STOCK TITAN

ZHENYU XU sells shares under 10b5-1 plan (SOPH)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

ZHENYU XU reported 10b5-1 sales of Common Stock under multiple transactions. The filing lists periodic 10b5-1 dispositions on 01/05/2026, 01/06/2026, 01/13/2026, 01/20/2026, 02/13/2026, 02/19/2026, and 03/13/2026, with reported share amounts of 2006, 3000, 4000, 608, 4000, 608, and 4000 respectively and per-trade proceeds shown in the filing.

The filing also lists 608 Restricted Stock Units to be sold by the issuer on 03/18/2026. Transactions were processed through Morgan Stanley Smith Barney LLC.

Positive

  • None.

Negative

  • None.

Insights

Structured sales under a 10b5-1 plan and an issuer-designated RSU sale are reported.

The filing documents multiple 10b5-1 sales by ZHENYU XU across seven dates in Jan–Mar 2026, listing per-transaction share counts: 2006, 3000, 4000, 608, 4000, 608, 4000. The excerpt shows per-trade cash amounts tied to each sale.

The excerpt also shows an issuer sale of 608 Restricted Stock Units on 03/18/2026 processed via Morgan Stanley Smith Barney LLC. Cash-flow treatment is the proceeds to the seller; further filing details would clarify net proceeds and any tax-withholding.

Forms indicate routine, pre-arranged dispositions rather than event-driven market activity.

The entries are labeled as 10b5-1 Sales, which the excerpt identifies by date and share count; such labeling typically denotes pre-planned trading instructions. The filing names the executing broker and records gross proceeds per trade.

Regulatory implications are routine disclosure; further filings may show aggregate totals or confirm whether these trades exhausted a plan, but timing and plan terms are not provided in the excerpt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What trades did ZHENYU XU report in the Form 144 for SOPH?

ZHENYU XU reported seven 10b5-1 sales on 01/05/2026 through 03/13/2026, totaling individual trades of 2006, 3000, 4000, 608, 4000, 608, and 4000 shares as listed in the filing.

Who executed the reported sales in this Form 144 for SOPH?

The trades were processed through Morgan Stanley Smith Barney LLC, listed with its New York address on the filing as the executing broker for the reported transactions.

Does the filing show any issuer securities being sold for SOPH?

Yes; the filing lists 608 Restricted Stock Units described as ‘Securities To Be Sold’ by the issuer with an effective date of 03/18/2026 in the excerpt.

Are the sales described as 10b5-1 in the Form 144 significant disclosure events?

They are routine disclosures of pre-arranged sales: the filing labels each disposition as 10b5-1 Sales across Jan–Mar 2026, which is standard for planned insider selling.
Sophia Genetics Sa

NASDAQ:SOPH

View SOPH Stock Overview

SOPH Rankings

SOPH Latest News

SOPH Latest SEC Filings

SOPH Stock Data

348.31M
67.30M
Health Information Services
Healthcare
Link
Switzerland
Rolle